1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted

2. Executive Summary
2.1. Market Snapshot: Global Pharmacogenomics Market
2.2. Global Pharmacogenomics Market, By Technology, 2023 (US$ Million)
2.3. Global Pharmacogenomics Market, By Application, 2023 (US$ Million)
2.4. Global Pharmacogenomics Market, By Geography, 2023 (US$ Million)
2.5. Attractive Investment Proposition by Geography, 2023

3. Pharmacogenomics Market: Competitive Analysis
3.1. Market Positioning of Key Pharmacogenomics Market Vendors
3.2. Strategies Adopted by Pharmacogenomics Market Vendors
3.3. Key Industry Strategies
4. Pharmacogenomics Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Pharmacogenomics Market Value, 2022 - 2032, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
4.6. Porter's Five Force Model
4.6.1. Supplier Power
4.6.2. Buyer Power
4.6.3. Threat Of Substitutes
4.6.4. Threat Of New Entrants
4.6.5. Competitive Rivalry
4.7. PESTEL Analysis
4.7.1. Political Landscape
4.7.2. Economic Landscape
4.7.3. Technology Landscape
4.7.4. Legal Landscape
4.7.5. Social Landscape

5. Pharmacogenomics Market: By Technology, 2022-2032, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2023 Versus 2032
5.3. Market Segmentation
5.3.1. Microarray
5.3.2. Sequencing
5.3.2.1. Sanger Sequencing
5.3.2.2. Pyrosequencing
5.3.2.3. Next-Generation Sequencing
5.3.3. Polymerase Chain Reaction
5.3.4. Other Technologies
5.3.4.1. Mass Spectrometry
5.3.4.2. Electrophoresis

6. Pharmacogenomics Market: By Application, 2022-2032, USD (Million)
6.1. Market Overview
6.2. Growth & Revenue Analysis: 2023 Versus 2032
6.3. Market Segmentation
6.3.1. Oncology
6.3.2. Cardiology
6.3.3. Pain Management
6.3.4. Neurological Disorders
6.3.5. Other Applications


7. North America Pharmacogenomics Market, 2022-2032, USD (Million)
7.1. Market Overview
7.2. Pharmacogenomics Market: By Technology, 2022-2032, USD (Million)
7.3. Pharmacogenomics Market: By Application, 2022-2032, USD (Million)
7.4.Pharmacogenomics Market: By Region, 2022-2032, USD (Million)
7.4.1.North America
7.4.1.1. U.S.
7.4.1.1.1. Pharmacogenomics Market: By Technology, 2022-2032, USD (Million)
7.4.1.1.2. Pharmacogenomics Market: By Application, 2022-2032, USD (Million)
7.4.1.2. Canada
7.4.1.2.1. Pharmacogenomics Market: By Technology, 2022-2032, USD (Million)
7.4.1.2.2. Pharmacogenomics Market: By Application, 2022-2032, USD (Million)
7.4.1.3. Rest of North America
7.4.1.3.1. Pharmacogenomics Market: By Technology, 2022-2032, USD (Million)
7.4.1.3.2. Pharmacogenomics Market: By Application, 2022-2032, USD (Million)

8. UK and European Union Pharmacogenomics Market, 2022-2032, USD (Million)
8.1. Market Overview
8.2. Pharmacogenomics Market: By Technology, 2022-2032, USD (Million)
8.3. Pharmacogenomics Market: By Application, 2022-2032, USD (Million)
8.4.Pharmacogenomics Market: By Region, 2022-2032, USD (Million)
8.4.1.UK and European Union
8.4.1.1. UK
8.4.1.1.1. Pharmacogenomics Market: By Technology, 2022-2032, USD (Million)
8.4.1.1.2. Pharmacogenomics Market: By Application, 2022-2032, USD (Million)
8.4.1.2. Germany
8.4.1.2.1. Pharmacogenomics Market: By Technology, 2022-2032, USD (Million)
8.4.1.2.2. Pharmacogenomics Market: By Application, 2022-2032, USD (Million)
8.4.1.3. Spain
8.4.1.3.1. Pharmacogenomics Market: By Technology, 2022-2032, USD (Million)
8.4.1.3.2. Pharmacogenomics Market: By Application, 2022-2032, USD (Million)
8.4.1.4. Italy
8.4.1.4.1. Pharmacogenomics Market: By Technology, 2022-2032, USD (Million)
8.4.1.4.2. Pharmacogenomics Market: By Application, 2022-2032, USD (Million)
8.4.1.5. France
8.4.1.5.1. Pharmacogenomics Market: By Technology, 2022-2032, USD (Million)
8.4.1.5.2. Pharmacogenomics Market: By Application, 2022-2032, USD (Million)
8.4.1.6. Rest of Europe
8.4.1.6.1. Pharmacogenomics Market: By Technology, 2022-2032, USD (Million)
8.4.1.6.2. Pharmacogenomics Market: By Application, 2022-2032, USD (Million)

9. Asia Pacific Pharmacogenomics Market, 2022-2032, USD (Million)
9.1. Market Overview
9.2. Pharmacogenomics Market: By Technology, 2022-2032, USD (Million)
9.3. Pharmacogenomics Market: By Application, 2022-2032, USD (Million)
9.4.Pharmacogenomics Market: By Region, 2022-2032, USD (Million)
9.4.1.Asia Pacific
9.4.1.1. China
9.4.1.1.1. Pharmacogenomics Market: By Technology, 2022-2032, USD (Million)
9.4.1.1.2. Pharmacogenomics Market: By Application, 2022-2032, USD (Million)
9.4.1.2. Japan
9.4.1.2.1. Pharmacogenomics Market: By Technology, 2022-2032, USD (Million)
9.4.1.2.2. Pharmacogenomics Market: By Application, 2022-2032, USD (Million)
9.4.1.3. India
9.4.1.3.1. Pharmacogenomics Market: By Technology, 2022-2032, USD (Million)
9.4.1.3.2. Pharmacogenomics Market: By Application, 2022-2032, USD (Million)
9.4.1.4. Australia
9.4.1.4.1. Pharmacogenomics Market: By Technology, 2022-2032, USD (Million)
9.4.1.4.2. Pharmacogenomics Market: By Application, 2022-2032, USD (Million)
9.4.1.5. South Korea
9.4.1.5.1. Pharmacogenomics Market: By Technology, 2022-2032, USD (Million)
9.4.1.5.2. Pharmacogenomics Market: By Application, 2022-2032, USD (Million)
9.4.1.6. Rest of Asia Pacific
9.4.1.6.1. Pharmacogenomics Market: By Technology, 2022-2032, USD (Million)
9.4.1.6.2. Pharmacogenomics Market: By Application, 2022-2032, USD (Million)

10. Latin America Pharmacogenomics Market, 2022-2032, USD (Million)
10.1. Market Overview
10.2. Pharmacogenomics Market: By Technology, 2022-2032, USD (Million)
10.3. Pharmacogenomics Market: By Application, 2022-2032, USD (Million)
10.4.Pharmacogenomics Market: By Region, 2022-2032, USD (Million)
10.4.1.Latin America
10.4.1.1. Brazil
10.4.1.1.1. Pharmacogenomics Market: By Technology, 2022-2032, USD (Million)
10.4.1.1.2. Pharmacogenomics Market: By Application, 2022-2032, USD (Million)
10.4.1.2. Mexico
10.4.1.2.1. Pharmacogenomics Market: By Technology, 2022-2032, USD (Million)
10.4.1.2.2. Pharmacogenomics Market: By Application, 2022-2032, USD (Million)
10.4.1.3. Rest of Latin America
10.4.1.3.1. Pharmacogenomics Market: By Technology, 2022-2032, USD (Million)
10.4.1.3.2. Pharmacogenomics Market: By Application, 2022-2032, USD (Million)

11. Middle East and Africa Pharmacogenomics Market, 2022-2032, USD (Million)
11.1. Market Overview
11.2. Pharmacogenomics Market: By Technology, 2022-2032, USD (Million)
11.3. Pharmacogenomics Market: By Application, 2022-2032, USD (Million)
11.4.Pharmacogenomics Market: By Region, 2022-2032, USD (Million)
11.4.1.Middle East and Africa
11.4.1.1. GCC
11.4.1.1.1. Pharmacogenomics Market: By Technology, 2022-2032, USD (Million)
11.4.1.1.2. Pharmacogenomics Market: By Application, 2022-2032, USD (Million)
11.4.1.2. Africa
11.4.1.2.1. Pharmacogenomics Market: By Technology, 2022-2032, USD (Million)
11.4.1.2.2. Pharmacogenomics Market: By Application, 2022-2032, USD (Million)
11.4.1.3. Rest of Middle East and Africa
11.4.1.3.1. Pharmacogenomics Market: By Technology, 2022-2032, USD (Million)
11.4.1.3.2. Pharmacogenomics Market: By Application, 2022-2032, USD (Million)

12. Company Profile
12.1. Abbott Laboratories, Inc.
12.1.1. Company Overview
12.1.2. Financial Performance
12.1.3. Product Portfolio
12.1.4. Strategic Initiatives
12.2. Affymetrix, Inc.
12.2.1. Company Overview
12.2.2. Financial Performance
12.2.3. Product Portfolio
12.2.4. Strategic Initiatives
12.3. AstraZeneca plc
12.3.1. Company Overview
12.3.2. Financial Performance
12.3.3. Product Portfolio
12.3.4. Strategic Initiatives
12.4. Assurex Health
12.4.1. Company Overview
12.4.2. Financial Performance
12.4.3. Product Portfolio
12.4.4. Strategic Initiatives
12.5. Bayer AG
12.5.1. Company Overview
12.5.2. Financial Performance
12.5.3. Product Portfolio
12.5.4. Strategic Initiatives
12.6. GeneDX
12.6.1. Company Overview
12.6.2. Financial Performance
12.6.3. Product Portfolio
12.6.4. Strategic Initiatives
12.7. F. Hoffmann-La Roche Ltd.
12.7.1. Company Overview
12.7.2. Financial Performance
12.7.3. Product Portfolio
12.7.4. Strategic Initiatives
12.8. Illumina, Inc
12.8.1. Company Overview
12.8.2. Financial Performance
12.8.3. Product Portfolio
12.8.4. Strategic Initiatives
12.9. Myriad Genetics, Inc
12.9.1. Company Overview
12.9.2. Financial Performance
12.9.3. Product Portfolio
12.9.4. Strategic Initiatives
12.10. Merck & Co
12.10.1. Company Overview
12.10.2. Financial Performance
12.10.3. Product Portfolio
12.10.4. Strategic Initiatives
12.11. GE Healthcare
12.11.1. Company Overview
12.11.2. Financial Performance
12.11.3. Product Portfolio
12.11.4. Strategic Initiatives
12.12. GlaxoSmithKline
12.12.1. Company Overview
12.12.2. Financial Performance
12.12.3. Product Portfolio
12.12.4. Strategic Initiatives
12.13. Johnson & Johnson
12.13.1. Company Overview
12.13.2. Financial Performance
12.13.3. Product Portfolio
12.13.4. Strategic Initiatives
12.14. Pfizer, Inc.
12.14.1. Company Overview
12.14.2. Financial Performance
12.14.3. Product Portfolio
12.14.4. Strategic Initiatives
12.15. Pathway Genomics
12.15.1. Company Overview
12.15.2. Financial Performance
12.15.3. Product Portfolio
12.15.4. Strategic Initiatives
12.16. Qiagen, Inc.
12.16.1. Company Overview
12.16.2. Financial Performance
12.16.3. Product Portfolio
12.16.4. Strategic Initiatives
12.17. Teva Pharmaceutical Industries Ltd
12.17.1. Company Overview
12.17.2. Financial Performance
12.17.3. Product Portfolio
12.17.4. Strategic Initiatives
12.18. Thermo Fisher Scientific
12.18.1. Company Overview
12.18.2. Financial Performance
12.18.3. Product Portfolio
12.18.4. Strategic Initiatives
12.19. Transgenomic, Inc.
12.19.1. Company Overview
12.19.2. Financial Performance
12.19.3. Product Portfolio
12.19.4. Strategic Initiatives
12.20. Other Notable Players
12.20.1. Company Overview
12.20.2. Financial Performance
12.20.3. Product Portfolio
12.20.4. Strategic Initiatives